ELEVATION IN RAT BRAIN HISTAMINE CONTENT AFTER FOCUSED MICROWAVE IRRADIATION 1

—Microwave irradiation focused on the head of small rodents is now widely used as a means of more accurately measuring acetylcholine, choline, cyclic AMP, and several other important brain constituents. Because of its probable neurotransmitter role and rapid turnover, a similar approach was taken to study brain histamine. Histamine was measured by a modified radio-enzymatic method and was found to be nearly tripled in brains from microwave treated rats, compared to decapitation controls (124 vs 42 ng/g). Possible explanations include a microwave-induced inactivation of histamine breakdown, a microwave-induced redistribution of previously unmeasured histamine, and microwave-induced histidine decarboxylation. Brain histamine remained unchanged up to 30 min after decapitation and microwave heated brains from decapitated rats also had elevated histamine levels, indicating that brain histamine levels in decapitated rats do not represent the remainder of a rapidly depleting pool. No evidence for previously unmeasured histamine was found. Furthermore, microwave irradiation did not enhance the formation of [ 3 H]histamine after intraventricular [ 3 H]histidine administration, indicating a lack of microwave-induced histidine decarboxylation. It is concluded that the elevation in rat brain histamine after focused microwave irradiation is probably not artifactual, although the mechanism responsible for this phenomenon remains obscure.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/65663/1/j.1471-4159.1977.tb09609.x.pd

Short Communication Opioid Analgesia in P450 Gene Cluster Knockout Mice: A Search for Analgesia-Relevant Isoforms

Number of references: 28 Number of words in Abstract: 240 Number of words in Introduction: 49

A reverse double-isotope enzymatic histamine assay: Advantages over single-isotope methods

High concentrations of codeine necessary to demonstrate histamine release from leukocytes interfere with histamine methylation, producing a concentration-dependent flattening of the histamine standard curves obtained from single-isotope (3H) assays. For this reason, the use of uniformly labeled 14C-histamine was investigated as an internal standard. This isotope serves as an internal standard and accurately predicts the recovery of histamine in the presence of up to 70% enzyme inhibition. The use of this reverse double-isotope procedure allows the assay of histamine without direct external recovery measurements in the presence of various drug concentrations.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/22813/1/0000371.pd

Human and mouse essentiality screens as a resource for disease gene discovery

The identification of causal variants in sequencing studies remains a considerable challenge that can be partially addressed by new gene-specific knowledge. Here, we integrate measures of how essential a gene is to supporting life, as inferred from viability and phenotyping screens performed on knockout mice by the International Mouse Phenotyping Consortium and essentiality screens carried out on human cell lines. We propose a cross-species gene classification across the Full Spectrum of Intolerance to Loss-of-function (FUSIL) and demonstrate that genes in five mutually exclusive FUSIL categories have differing biological properties. Most notably, Mendelian disease genes, particularly those associated with developmental disorders, are highly overrepresented among genes non-essential for cell survival but required for organism development. After screening developmental disorder cases from three independent disease sequencing consortia, we identify potentially pathogenic variants in genes not previously associated with rare diseases. We therefore propose FUSIL as an efficient approach for disease gene discovery. Discovery of causal variants for monogenic disorders has been facilitated by whole exome and genome sequencing, but does not provide a diagnosis for all patients. Here, the authors propose a Full Spectrum of Intolerance to Loss-of-Function (FUSIL) categorization that integrates gene essentiality information to aid disease gene discovery

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Genomic reconstruction of the SARS-CoV-2 epidemic in England.

The evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus leads to new variants that warrant timely epidemiological characterization. Here we use the dense genomic surveillance data generated by the COVID-19 Genomics UK Consortium to reconstruct the dynamics of 71 different lineages in each of 315 English local authorities between September 2020 and June 2021. This analysis reveals a series of subepidemics that peaked in early autumn 2020, followed by a jump in transmissibility of the B.1.1.7/Alpha lineage. The Alpha variant grew when other lineages declined during the second national lockdown and regionally tiered restrictions between November and December 2020. A third more stringent national lockdown suppressed the Alpha variant and eliminated nearly all other lineages in early 2021. Yet a series of variants (most of which contained the spike E484K mutation) defied these trends and persisted at moderately increasing proportions. However, by accounting for sustained introductions, we found that the transmissibility of these variants is unlikely to have exceeded the transmissibility of the Alpha variant. Finally, B.1.617.2/Delta was repeatedly introduced in England and grew rapidly in early summer 2021, constituting approximately 98% of sampled SARS-CoV-2 genomes on 26 June 2021

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome